CN104288704A - 一种治疗酒精肝的中药组合物及其制备方法 - Google Patents
一种治疗酒精肝的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104288704A CN104288704A CN201410595571.4A CN201410595571A CN104288704A CN 104288704 A CN104288704 A CN 104288704A CN 201410595571 A CN201410595571 A CN 201410595571A CN 104288704 A CN104288704 A CN 104288704A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- alcoholic liver
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims description 11
- 208000022309 Alcoholic Liver disease Diseases 0.000 title abstract description 3
- 239000002131 composite material Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 241000756943 Codonopsis Species 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 44
- 210000004185 liver Anatomy 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 241000628997 Flos Species 0.000 claims description 27
- 230000001476 alcoholic effect Effects 0.000 claims description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000167230 Lonicera japonica Species 0.000 abstract 1
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 208000010706 fatty liver disease Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical group C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 11
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 10
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 10
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗酒精肝的中药组合物,属于中医药技术领域。其由如下重量份的原料药组成:陈皮15-20份、甘草5-12份、金银花10-20份、山栀5-10份、茯苓10-20份、党参10-20份、五味子1.5-6份、郁金15-20份、山药15-30份、枸杞子15-20份、菊花5-9份。本发明与现有技术相比,疗效显著,制备简单,基本无毒,原料易得,适于大众化使用,具有很好的应用前景。
Description
技术领域
本发明属于中医药技术领域,具体涉及一种治疗酒精肝的中药组合物。
背景技术
近年来,随着人民生活水平的提高和社交圈的扩大,全球酒的消费量猛增。同时,酒精肝的发生亦显著增加。在中国由于饮酒导致酒精肝的发生率也呈明显上升趋势,已成为不容忽视的隐型杀手。酗酒能毒害肝脏,损害肝功能。过量饮酒可加重肝脏负担,使肝细胞受损变性,最终导致肝硬变,医学上称之为“酒精肝”。 中医一般认为本病中医归属“积聚”、“痰浊”、“瘀血”、“胁痛”等病范畴,其病因病机为纵酒过度,损伤脾胃,湿浊内生,郁而化热,熏蒸肝胆,胆汁不循常道,浸淫肌肤而发黄。目前治疗酒精肝的药物很多,如西药和静脉注射等,众所周知,西药有副作用,长期用药,带来的结果往往是身体机能退化和药物抵抗,会使身体产生不良反应,还能对药物形成依赖性。而中医药治疗脂肪肝具有疗效稳定、持久、不良反应少等优势。
发明内容
本发明的目的是针对现有治疗酒精肝药物技术的不足,提供一种疗效好,副作用小,标本兼治的治疗酒精肝的中药组合物。
本发明采用如下技术方案。
一种治疗酒精肝的中药组合物,由如下重量份的原料药组成:陈皮15-20份、甘草5-12份、金银花10-20份、山栀5-10份、茯苓10-20份、党参10-20份、五味子1.5-6份、郁金15-20份、山药15-30份、枸杞子15-20份、菊花5-9份。
优选地,上述治疗酒精肝的中药组合物,由如下重量份的原料药组成:陈皮16-20份、甘草6-11份、金银花12-20份、山栀6-10份、茯苓12-18份、党参12-18份、五味子2-6份、郁金16-20份、山药18-28份、枸杞子16-20份、菊花6-9份。
进一步优选地,上述治疗酒精肝的中药组合物,由如下重量份的原料药组成:陈皮18-20份、甘草8-10份、金银花15-20份、山栀8-10份、茯苓15-18份、党参15-18份、五味子2-5份、郁金18-20份、山药20-25份、枸杞子18-20份、菊花7-9份。
最优选地,上述治疗酒精肝的中药组合物,由如下重量份的原料药组成:陈皮19份、甘草9份、金银花18份、山栀9份、茯苓17份、党参17份、五味子4份、郁金19份、山药23份、枸杞子19份、菊花8份。
根据中医药史料记载,上述中药材具有如下药理活性和功能主治:
陈皮,具有理气降逆,调中开胃,燥湿化痰之功效,主治脾胃气滞湿阻,胸膈满闷,脘腹胀痛,不思饮食,呕吐秽逆,二便不利,肺气阻滞,咳嗽痰多等症。
甘草,性味:甘,平。归脾、胃、肺经。功效 :益气补中,缓急止痛,润肺止咳,泻火解毒,调和诸药。
金银花,性甘,寒。归肺、心、胃经。清热解毒,凉散风热。用于痈肿疔疮,喉痹,丹毒,热毒血痢,风热感冒,温病发热。
山栀,具有泻火除烦,清热利湿,凉血解毒等功效,主治热病心烦,肝火目赤,湿热黄疳,疮疡肿毒等症。
茯苓,具有渗湿利水,健脾和胃,宁心安神的功效,可治小便不利,水肿胀满,痰饮咳逆,呕逆,健忘等症。
党参,具有补中益气,健脾益肺等功效,用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴等症。
五味子,收敛固涩,益气生津,补肾宁心。用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。
郁金,郁金,味辛、苦,性寒。归肝、心、肺经,具有行气化瘀、清心解郁、利胆退黄、活血止痛、行气解郁、清心凉血之用。《本草汇言》中记载 :郁金,清气化痰,散瘀血之药也。其性轻扬,能散郁滞,顺逆气,上达高巅,善行下焦,心肺肝胃气血火痰郁遏不行者最验,故治胸胃膈痛,两胁胀满,肚腹攻疼,饮食不思等证。又治经脉逆行,吐血衄血,唾血血腥。此药能降气,气降则火降,而痰与血,亦各循其所安之处而归原矣。
山药,补脾养胃,生津益肺,补肾涩精。用于脾虚食少,久泻不止,肺虚喘咳,肾虚遗精,带下,尿频,虚热消渴。麸炒山药补脾健胃。用于脾虚食少,泄泻便溏,白带过多。
枸杞子,味甘,性平。中医学认为其能补肝阴、养肝血、益精明目。现代药理研究证明:枸杞子能降血糖,抑制脂肪在肝细胞内沉积,促进肝细胞新生,并有降压功效。
菊花,性甘、苦,微寒。归肺、肝经。散风清热,平肝明目。用于风热感冒,头痛眩晕,目赤肿痛,眼目昏花。《本草经疏》:“菊花专制风木,故为去风之要药。苦可泄热,甘能益血,甘可解毒,平则兼辛,故亦散结,苦入心、小肠,甘入脾、胃,平辛走肝、胆,兼入肺与大肠。其主风头眩、肿痛、目欲脱、泪出、皮肤死肌、恶风、湿痹者,诸风掉眩,皆属肝木,风药先入肝,肝开窍于目,风为阳邪,势必走上,血虚则热,热则生风,风火相搏故也。”
本发明对上述诸味中药及其重量份数进行了组合,其中枸杞子、山药和五味子补肾健脾,陈皮和郁金疏肝理气疏活血,当参和茯苓化痰利湿,山栀、菊花和金银花清热解毒,再加上甘草调和诸味药,该组方整体起到疏肝解郁、健脾消导、活血化淤、化痰祛湿的功效。优选的条件是中药配伍使用后药物治疗效果的增强。
制备本发明中药组合物的方法如下:取上述重量组分的各药材,加药材总重量的5-15倍的水,浸泡10-60分钟,煎煮1-4次,每次1-3小时,滤过,合并滤液,滤液减压浓缩至相对密度1.05-1.25的浸膏,该相对密度是在60摄氏度下的检测结果,加入乙醇至含醇量为60-90%(v/v),静置24小时,取上清液,回收乙醇至浓缩,即得。本发明上述中药组合物可以进一步制备成临床上常用的药物制剂,优选为合剂、片剂、胶囊剂。所述的制成合剂、片剂、胶囊剂的制备方法为现有技术。
通过临床应用研究发现,由上述中药材制备而成的药物组合物在治疗酒精肝患者方面获得了满意的疗效。因此,本发明的第二个目的在于提供一种医药新用途,即上述中药组合物在制备治疗酒精肝药物中的应用。
本发明通过考察本发明中药组合物对大鼠酒精性脂肪肝模型的治疗实验,发现本发明提供的中药组合物能够明显降低酒精性脂肪肝大鼠模型的AST和ALT,能够显著降低脂肪大鼠模型的TG、TC和LDL-C,并且能够显著降低模型大鼠的肝脏指数。这表明本发明的中药组合物对治疗酒精肝疾病时作用全面、具有明显协同作用,取得了预料不到的药物疗效。
总之,本发明与现有技术相比,具有很好治疗酒精肝肝的活性。本发明作为酒精肝治疗药物使用时,药物作用全面,在疏肝解郁、健脾消导的同时,还能够取得活血化淤、化痰祛湿的功效,能够迅速使脂肪肝患者病情好转;并且本发明中药组合物制备简单,基本无毒,原料易得,适于大众化使用,具有很好的应用前景。
具体实施方式
以下通过具体实施方式进一步描述本发明,但本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的实质内容和范围内,对本发明所述的中药组合物进行适当改进、替换功效相同的组分,对于本领域技术人员来说是显而易见的,它们都被视为包括在本发明的范围之内。
实施例1 本发明的中药组合物合剂
处方:陈皮15g、甘草5g、金银花10g、山栀5g、茯苓10g、党参10g、五味子1.5g、郁金15g、山药15g、枸杞子15g、菊花5g。
制备方法:取上述重量组分的各药材,加药材总重量的10倍的水,浸泡60分钟,煎煮4次,每次0.5小时,滤过,合并滤液,滤液减压浓缩至相对密度1.05的浸膏,该相对密度是在60摄氏度下的检测结果,加入乙醇至含醇量为86%(v/v),静置24小时,取上清液,回收乙醇浓缩,加水至1000ml,搅匀,分装,流通蒸汽灭菌35min,即得合剂。
实施例2 本发明的中药组合物片剂
处方:陈皮17g、甘草8g、金银花16g、山栀7g、茯苓14g、党参14g、五味子3g、郁金15g、山药20g、枸杞子16g、菊花6g。
制备方法:取上述重量组分的各药材,加药材总重量的8倍的水,浸泡45分钟,煎煮2次,每次1小时,滤过,合并滤液,滤液减压浓缩至相对密度1.2的浸膏,该相对密度是在60摄氏度下的检测结果,加入乙醇至含醇量为78%(v/v),静置24小时,取上清液,回收乙醇至浓缩,真空干燥、制粒,压片即得。
实施例3 本发明中药组合物胶囊
处方:陈皮19g、甘草9g、金银花18g、山栀9g、茯苓17g、党参17g、五味子4g、郁金19g、山药23g、枸杞子19g、菊花8g。
制备方法:取上述重量组分的各药材,加药材总重量的5倍的水,浸泡30分钟,煎煮3次,每次1.5小时,滤过,合并滤液,滤液减压浓缩至相对密度1.25的浸膏,该相对密度是在60摄氏度下的检测结果,加入乙醇至含醇量为90%(v/v),静置24小时,取上清液,回收乙醇至浓缩,真空干燥,制粒,装胶囊即得。
实施例4本发明中药组合物对酒精性脂肪肝的治疗
1、酒精性脂肪肝模型的制备
SD大鼠,雄性,体重240±20g,采用造瘘管注入酒精的方法造模。除正常对照组正常饲养外,其余各组在术前8h禁食,在2%戊巴比妥(50mg/kg体重)麻醉下,于上腹正中切开腹壁长1.5-2.0cm。于胃前壁,胃体胃底交界处切开胃壁,置入直径2mm带膨大头的塑料导管,管周缝合,导管经侧腹壁引出至皮下,皮下做隧道引至后颈后,破皮引出,并于皮肤缝合固定导管。术后饲养方法同正常对照组,肌注抗生素3天后经胃造瘘管注入40%酒精,每次2ml,1日3次,逐渐增至每次3ml(以注入酒精后醉倒,清醒1h后再注入为参考)。造模4周。
2、分组与给药
模型大鼠适应性饲养1周后,随机分成正常组、模型组以及给药组,具体分组情况如下,每组5只。每天下午14:00时灌胃药物,剂量如下:
正常对照组:灌胃给予同体积的蒸馏水;
模型对照组:灌胃给予同体积的蒸馏水;
水飞蓟宾组:灌胃给予25mg/(kg.d)水飞蓟宾;
实施例1组:灌胃给予25mg/(kg.d)本发明实施例1所制备中药组合物合剂;
实施例2组:灌胃给予25mg/(kg.d)本发明实施例2所制备中药组合物合剂;
实施例3组:灌胃给予25mg/(kg.d)本发明实施例3所制备中药组合物合剂。
3、检测指标
末次给药后,戊巴比妥钠麻醉大鼠,解剖,腹主静脉取血测定生化指标,取肝脏进行称重。
3.1.血脂
试验结果表明(详见表1),实施例组的总胆固醇、甘油三酯、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇的水平与大鼠酒精性脂肪肝模型组相比有显著性差异或极显著性差异,与水飞蓟宾组相比也具有显著性差异或极显著性差异(高密度脂蛋白水平除外),这说明本发明中药组合物,在大鼠酒精性脂肪肝模型上,在降低TG、TC和LDL-C上取得了很好的作用。
表1 本发明中药组合物对大鼠血脂的影响
与模型组比较,*P<0.05;与模型组比较,**P<0.01;
与水飞蓟宾组比较,#P<0.05;与水飞蓟宾组比较, ##P<0.01。
3.3.肝指数
试验结果表明(详见表2),酒精性脂肪肝模型组大鼠肝指数与正常组相比有极显著性差异,各给药组的大鼠的肝指数与模型组相比有极显著性差异,尤其是,实施例3组与水飞蓟宾组相比有显著性差异或极显著性差异,这说明本发明中药组合物各中药在大鼠酒精性脂肪肝模型上,在降低肝脏指数这个指标上取得了很好的协同作用。
表2 本发明中药组合物对大鼠脏器指数的影响
与正常组比较,¥P<0.05;与正常组比较,¥¥P<0.01;
与模型组比较,*P<0.05;与模型组比较,**P<0.01;
与水飞蓟宾组比较,#P<0.05;与水飞蓟宾组比较, ##P<0.01。
3.3肝功能
试验结果表明(详见表3),酒精性脂肪肝模型组大鼠血清ALT、AST含量与正常组相比大幅度升高,各给药组的大鼠血清ALT、AST含量与模型组相比明显下降,尤其是,实施例3组与模型组相比具有极显著性差异,与水飞蓟宾组相比有极显著性差异,这说明本发明中药组合物各中药在对大鼠酒精性脂肪肝的预防或治疗上取得了协同性的作用。
表3 本发明中药组合物对大鼠模型肝功能的影响
与模型组比较,*P<0.05;与模型组比较,**P<0.01;
与水飞蓟宾组比较,#P<0.05;与水飞蓟宾组比较, ##P<0.01。
Claims (7)
1.一种治疗酒精肝的中药组合物,其特征在于由如下重量份的原料药组成:陈皮15-20份、甘草5-12份、金银花10-20份、山栀5-10份、茯苓10-20份、党参10-20份、五味子1.5-6份、郁金15-20份、山药15-30份、枸杞子15-20份、菊花5-9份。
2.如权利要求1所述的治疗酒精肝的中药组合物,其特征在于由如下重量份的原料药组成:陈皮16-20份、甘草6-11份、金银花12-20份、山栀6-10份、茯苓12-18份、党参12-18份、五味子2-6份、郁金16-20份、山药18-28份、枸杞子16-20份、菊花6-9份。
3.如权利要求2所述的治疗酒精肝的中药组合物,其特征在于由如下重量份的原料药组成:陈皮18-20份、甘草8-10份、金银花15-20份、山栀8-10份、茯苓15-18份、党参15-18份、五味子2-5份、郁金18-20份、山药20-25份、枸杞子18-20份、菊花7-9份。
4.如权利要求3所述的治疗酒精肝的中药组合物,其特征在于由如下重量份的原料药组成:陈皮19份、甘草9份、金银花18份、山栀9份、茯苓17份、党参17份、五味子4份、郁金19份、山药23份、枸杞子19份、菊花8份。
5.如权利要求1-4任一所述的治疗酒精肝的中药组合物的制备方法,其特征在包括如下步骤:取重量组分的各药材,加药材总重量的5-15倍的水,浸泡10-60分钟,煎煮1-4次,每次1-3小时,滤过,合并滤液,滤液减压浓缩至相对密度1.05-1.25的浸膏,该相对密度是在60摄氏度下的检测结果,加入乙醇至含醇量为60-90%v/v,静置24小时,取上清液,回收乙醇至浓缩,即得。
6.如权利要求1-4任一所述的治疗酒精肝的中药组合物,其特征在于:所述中药组合物可以制成合剂、片剂、胶囊剂。
7.权利要求1-4任一所述的中药组合物在制备治疗酒精肝药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410595571.4A CN104288704A (zh) | 2014-10-30 | 2014-10-30 | 一种治疗酒精肝的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410595571.4A CN104288704A (zh) | 2014-10-30 | 2014-10-30 | 一种治疗酒精肝的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104288704A true CN104288704A (zh) | 2015-01-21 |
Family
ID=52308815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410595571.4A Pending CN104288704A (zh) | 2014-10-30 | 2014-10-30 | 一种治疗酒精肝的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104288704A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770565A (zh) * | 2016-04-29 | 2016-07-20 | 何蓉蓉 | 治疗肝损伤和增强体内抗氧化酶体活性的组合物及其应用 |
JP7526363B2 (ja) | 2021-03-10 | 2024-07-31 | チャン グン メディカル ファンデーション | アルコールの二日酔いを治療又は低減する薬物組成物及びその用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103120742A (zh) * | 2013-02-28 | 2013-05-29 | 石家庄市第五医院 | 一种用于治疗脂肪肝和酒精肝的中药胶囊及其制备方法 |
-
2014
- 2014-10-30 CN CN201410595571.4A patent/CN104288704A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103120742A (zh) * | 2013-02-28 | 2013-05-29 | 石家庄市第五医院 | 一种用于治疗脂肪肝和酒精肝的中药胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
张雄飞等: "陈皮提取物对酒精肝的保护作用", 《当代医学(学术版)》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105770565A (zh) * | 2016-04-29 | 2016-07-20 | 何蓉蓉 | 治疗肝损伤和增强体内抗氧化酶体活性的组合物及其应用 |
JP7526363B2 (ja) | 2021-03-10 | 2024-07-31 | チャン グン メディカル ファンデーション | アルコールの二日酔いを治療又は低減する薬物組成物及びその用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103860958B (zh) | 一种用于治疗痤疮的中药组合物 | |
CN106390013A (zh) | 一种抑制结直肠癌肝转移的复方中药组合物其制备方法与应用 | |
CN102293900B (zh) | 治疗小儿腹泻的中药 | |
CN102885975B (zh) | 一种治疗糖尿病的中药组合物 | |
CN103432412B (zh) | 一种治疗乳腺增生的药物及其制备方法 | |
CN103495019B (zh) | 一种养心安神中药制剂及其制备方法 | |
CN105213974A (zh) | 一种治疗淋巴瘤的中药组合物及其应用 | |
CN104435535B (zh) | 一种治疗ⅱ型糖尿病的保健药品 | |
CN104288704A (zh) | 一种治疗酒精肝的中药组合物及其制备方法 | |
CN103751745B (zh) | 一种治疗荨麻疹的中药混合物 | |
CN102552657B (zh) | 一种用于治疗鸡新城疫病的中药组合物 | |
CN105343498A (zh) | 一种用于润肺的中药制剂及其制备方法与应用 | |
CN108096344A (zh) | 一种治疗鼻炎的中药组合物 | |
CN104107352A (zh) | 一种降血压用中草药及其服用方法 | |
CN103495101B (zh) | 一种用于治疗胃痛的中药组合物 | |
CN103028028B (zh) | 一种治疗原发性肝癌的中药 | |
CN104587278A (zh) | 一种治疗胸腔积液的中药组合物及制备方法 | |
CN105362993A (zh) | 治疗鹦鹉鱼白点病的酊剂及其制备方法 | |
CN105056160A (zh) | 一种治疗奶牛缺乳症的药物组合物及其制备方法 | |
CN105456995A (zh) | 一种治疗新生儿黄疸的中药组合物 | |
CN105147944A (zh) | 一种中药组合物、其制剂及其制备方法和应用 | |
CN104825735A (zh) | 补肾保健药酒 | |
CN104547613A (zh) | 一种药物组合物在制备治疗高血压肾病药物中的用途 | |
CN104524359A (zh) | 一种中药组合物、其制备方法及应用 | |
CN104435980B (zh) | 一种治疗青少年前庭神经炎的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yipan Inventor after: Qiu Shanxiao Inventor before: Cui Yinfang |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |